首页> 外文期刊>Memórias do Instituto Oswaldo Cruz >A molecular platform for the diagnosis of multidrug-resistant and pre-extensively drug-resistant tuberculosis based on single nucleotide polymorphism mutations present in Colombian isolates of Mycobacterium tuberculosis
【24h】

A molecular platform for the diagnosis of multidrug-resistant and pre-extensively drug-resistant tuberculosis based on single nucleotide polymorphism mutations present in Colombian isolates of Mycobacterium tuberculosis

机译:基于哥伦比亚结核分枝杆菌分离株中存在的单核苷酸多态性突变的多耐药和广泛耐药结核病诊断分子平台

获取原文
           

摘要

Developing a fast, inexpensive, and specific test that reflects the mutations present in Mycobacterium tuberculosis isolates according to geographic region is the main challenge for drug-resistant tuberculosis (TB) control. The objective of this study was to develop a molecular platform to make a rapid diagnosis of multidrug-resistant (MDR) and extensively drug-resistant TB based on single nucleotide polymorphism (SNP) mutations present in the rpoB , katG , inhA , ahpC , and gyrA genes from Colombian M. tuberculosis isolates. The amplification and sequencing of each target gene was performed. Capture oligonucleotides, which were tested before being used with isolates to assess the performance, were designed for wild type and mutated codons, and the platform was standardised based on the reverse hybridisation principle. This method was tested on DNA samples extracted from clinical isolates from 160 Colombian patients who were previously phenotypically and genotypically characterised as having susceptible or MDR M. tuberculosis . For our method, the kappa index of the sequencing results was 0,966, 0,825, 0,766, 0,740, and 0,625 for rpoB , katG , inhA , ahpC , and gyrA, respectively. Sensitivity and specificity were ranked between 90-100% compared with those of phenotypic drug susceptibility testing. Our assay helps to pave the way for implementation locally and for specifically adapted methods that can simultaneously detect drug resistance mutations to first and second-line drugs within a few hours.
机译:开发一种快速,廉价且特定的测试方法,以反映根据地区划分的结核分枝杆菌分离株中存在的突变,是控制耐药结核病(TB)的主要挑战。这项研究的目的是基于rpoB,katG,inhA,ahpC和rpoB中存在的单核苷酸多态性(SNP)突变,开发一种分子平台,以快速诊断耐多药(MDR)和广泛耐药的TB。来自哥伦比亚结核分枝杆菌的gyrA基因分离株。进行每个靶基因的扩增和测序。为与野生型和突变密码子一起设计了捕获寡核苷酸,将其与分离物一起使用以评估其性能,然后对其进行了测试,并根据反向杂交原理对平台进行了标准化。对该方法进行了测试,该DNA样品是从160例哥伦比亚患者的临床分离物中提取的,这些患者以前在表型和基因型上表现为易感或耐MDR结核分枝杆菌。对于我们的方法,rpoB,katG,inhA,ahpC和gyrA的测序结果的kappa指数分别为0,966、0.825、0.766、0.740和0.625。与表型药物敏感性测试相比,敏感性和特异性介于90-100%之间。我们的检测方法有助于为本地实施和专门适应的方法铺平道路,这些方法可以在几个小时内同时检测出对一线和二线药物的耐药性突变。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号